Showing results (751-760 of 871) with videos related to
Sort By:
Pageof 88
Biomarker Research|December 21, 2021
Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancerChi T Viet, Xinyu Zhang, Ke Xu, et al.Annals of Neurology|January 5, 2023
Monkeypox-Associated Central Nervous System Disease: A Case Series and ReviewKelli M Money, T Allen Barnett, Samuel Rapaka, et al.Biomarker Research|June 6, 2021
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinomaChi T Viet, Gary Yu, Kesava Asam, et al.Science (New York, N.Y.)|June 23, 2018
Assessment of methane emissions from the U.S. oil and gas supply chainRamón A Alvarez, Daniel Zavala-Araiza, David R Lyon, et al.Advanced Biology|August 4, 2022
Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral CancerColeen Doan, Bradley E Aouizerat, Yi Ye, et al.Nature Medicine|February 11, 2004
HIV evolution: CTL escape mutation and reversion after transmissionA J Leslie, K J Pfafferott, P Chetty, et al.Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.Cell Reports|July 18, 2023
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neckNupur Nigam, Benjamin Bernard, Samantha Sevilla, et al.Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.Pageof 88